Anti-SIGLEC15 mAb BCG008

BCG008-A More Potent Fully Human anti-Siglec-15 Antibody with Prolongated PK profile in Oncotherapy.

Download Brochure Request a Quote

on this page

  • Highlights of Anti-SIGLEC15 mAb
  • About SIGLEC15

Posters

View All
    Highlights of Anti-SIGLEC15 mAb
    • BCG008 is a potential best-in-class fully human anti-Siglec-15 antibody generated from Siglec-15 Knockout RenMab Mouse.
    • The binding epitope of BCG008 is different from NC318.
    • BCG008 has a longer half-life than NC318 (9.79 days VS 4.52 days) and potential better developability with more ideal PI value.
    • BCG008 has superior T-cell restoration activity than NC318.
    • BCG008 has better tumor inhibition efficacy and good safety than NC318
    In Vitro： BCG008 has higher affinity for SIGLEC15
    In Vitro： BCG008 showed better effects of restoring PBMC proliferation
    In Vivo： BCG008 has has better tumor inhibition efficacy and good safety than PC
    In Vivo： BCG008 has better PK profile than 5G12 in B-hSiglec-15 mice
    About SIGLEC15

    Sialic acid-binding Ig-like lectin 15, or Siglec-15, is identified as a critical immune suppressor. Siglec-15 expression is normally limited to certain myeloid cells, but it can be upregulated in a variety of tumors and on tumor-infiltrating myeloid cells. Siglec-15 significantly inhibits antigen-specific T cell responses both in vitro and in vivo. Conversely, genetic ablation of Siglec-15 promotes anti-tumor responses. Therefore, a Siglec-15-targeting blocking antibody could represent a novel class of anti-tumor immunotherapy.

    Learn more about the RenLite and ADC platform.